Skip to main content
. 2021 Aug 31;71:103547. doi: 10.1016/j.ebiom.2021.103547

Fig. 6.

Fig 6

Kaplan-Meier curves for overall survival (OS) in the high-risk subgroup of the validation set (n = 394). (a) Kaplan-Meier curves for OS according to the CD8+ T-lymphocyte fraction in patients with high-risk stage ΙΙΙ colorectal cancer (CRC). 5-year OS: 70% (95% CI 63–78) for the patients with high CD8+ T-lymphocyte fraction versus 59% (95% CI 53–67) for the patients with low CD8+ T-lymphocyte fraction (Mantel-Cox log-rank test, P = 0.018). (b) Kaplan-Meier curves for OS according to stroma fraction. 5-year OS: 69% (95% CI 63–76) for the patients with low stroma fraction versus 56% (95% CI 47–65) for the patients with high stroma fraction (Mantel-Cox log-rank test, P = 0.004). (c) Kaplan-Meier curves for OS according to combined CD8+ T-lymphocyte fraction/stroma fraction. 5-year OS: 74% (95% CI 66–82) for the patients with high CD8+ T-lymphocyte fraction/low stroma fraction, 62% (95% CI 56-70) for the patients with combined low CD8+ T-lymphocyte fraction/low stroma fraction or combined high CD8+ T-lymphocyte fraction/high stroma fraction, and 42% (95% CI 28–63) for the patients with low CD8+ T-lymphocyte fraction/high stroma fraction (Mantel-Cox log-rank test, P < 0.001). High-risk stage ΙΙΙ CRC, pathological tumor stage (pT) 3 pathological lymph node stage (pN) 1 with either lymphovascular invasion (L+) or venous vascular invasion (V+); pT4; or pN2. HR, hazard risk; CI, confidence interval.